[EN] NOVEL TRICYCLIC COMPOUNDS AS BCR-ABL INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES UTILISÉS COMME INHIBITEURS DE BCR-ABL
申请人:ASCENTAGE PHARMA SUZHOU CO LTD
公开号:WO2021018195A1
公开(公告)日:2021-02-04
The present disclosure provides compounds represented by Formula (I), or an enantiomer or diastereomer, or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, L, Ar, R1, R2, R3 R4, R5, R6, m, and p are defined herein. Compounds of Formula (I) are BCR-ABL inhibitors. BCR-ABL inhibitors are useful for the treatment of cancer and other diseases.
本公开提供由式(I)表示的化合物,或其对映体或二对映体,或其药用可接受的盐,其中X、Y、Z、L、Ar、R1、R2、R3、R4、R5、R6、m和p在此定义。式(I)的化合物是BCR-ABL抑制剂。BCR-ABL抑制剂对于治疗癌症和其他疾病非常有用。